Patent 10543208 was granted and assigned to EpicentRx on January, 2020 by the United States Patent and Trademark Office.
The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.